Compare Cadila Healthcare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs VENUS REMEDIES - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE VENUS REMEDIES CADILA HEALTHCARE/
VENUS REMEDIES
 
P/E (TTM) x 14.4 -1.5 - View Chart
P/BV x 2.8 0.1 2,603.4% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 CADILA HEALTHCARE   VENUS REMEDIES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
VENUS REMEDIES
Mar-18
CADILA HEALTHCARE/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs558126 443.2%   
Low Rs36261 591.7%   
Sales per share (Unadj.) Rs116.3301.8 38.5%  
Earnings per share (Unadj.) Rs17.9-24.9 -71.8%  
Cash flow per share (Unadj.) Rs23.12.5 909.0%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.4293.3 29.1%  
Shares outstanding (eoy) m1,023.7412.34 8,296.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.00.3 1,276.1%   
Avg P/E ratio x25.7-3.8 -684.4%  
P/CF ratio (eoy) x19.936.7 54.1%  
Price / Book Value ratio x5.40.3 1,688.3%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,6641,154 40,792.9%   
No. of employees `00011.80.9 1,277.7%   
Total wages/salary Rs m18,545393 4,717.6%   
Avg. sales/employee Rs Th10,072.74,026.1 250.2%   
Avg. wages/employee Rs Th1,569.1425.0 369.2%   
Avg. net profit/employee Rs Th1,547.7-331.8 -466.5%   
INCOME DATA
Net Sales Rs m119,0493,724 3,196.7%  
Other income Rs m1,13223 5,031.1%   
Total revenues Rs m120,1813,747 3,207.7%   
Gross profit Rs m28,475395 7,212.5%  
Depreciation Rs m5,388338 1,592.7%   
Interest Rs m911354 257.1%   
Profit before tax Rs m23,308-275 -8,466.4%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,64432 17,860.8%   
Profit after tax Rs m18,292-307 -5,960.2%  
Gross profit margin %23.910.6 225.6%  
Effective tax rate %24.2-11.5 -211.0%   
Net profit margin %15.4-8.2 -186.4%  
BALANCE SHEET DATA
Current assets Rs m82,0052,638 3,109.0%   
Current liabilities Rs m60,7202,305 2,634.7%   
Net working cap to sales %17.98.9 199.9%  
Current ratio x1.41.1 118.0%  
Inventory Days Days73135 54.0%  
Debtors Days Days9846 212.2%  
Net fixed assets Rs m83,7034,871 1,718.5%   
Share capital Rs m1,024123 829.8%   
"Free" reserves Rs m86,4213,496 2,472.2%   
Net worth Rs m87,4453,619 2,416.2%   
Long term debt Rs m25,5511,374 1,859.1%   
Total assets Rs m180,6537,509 2,406.0%  
Interest coverage x26.60.2 11,922.9%   
Debt to equity ratio x0.30.4 76.9%  
Sales to assets ratio x0.70.5 132.9%   
Return on assets %10.60.6 1,683.8%  
Return on equity %20.9-8.5 -246.7%  
Return on capital %22.01.6 1,389.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m42,6830-   
Fx outflow Rs m11,242517 2,176.6%   
Net fx Rs m31,441-517 -6,087.3%   
CASH FLOW
From Operations Rs m9,193514 1,787.1%  
From Investments Rs m-9,737-123 7,909.8%  
From Financial Activity Rs m515-387 -133.0%  
Net Cashflow Rs m-294 -690.5%  

Share Holding

Indian Promoters % 74.8 32.9 227.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.2 4,611.1%  
FIIs % 5.9 0.6 1,017.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 66.4 16.6%  
Shareholders   44,069 20,121 219.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   FDC LTD.  UNICHEM LAB  WYETH LTD  DIVIS LABORATORIES  ALEMBIC LTD  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 18, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - ELDER PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS